Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Open-label, Multicenter Study to Evaluate the Peginterferon, Comparing to Nucleos(t)Ide Analogues, in Reducing the Incidence of HCC in Chronic Hepatitis B Patients With Intermediate to High Liver Cancer Risks

NCT05671315 is registered in ClinicalTrials.gov with Qing XIe as lead sponsor.

NCT NCT05671315
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05671315 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Open-label, Multicenter Study to Evaluate the Peginterferon, Comparing to Nucleos(t)Ide Analogues, in Reducing the Incidence of HCC in Chronic Hepatitis B Patients With Intermediate to High Liver Cancer Risks
Lead sponsor
Qing XIe
Phase
Not applicable
Overall status
Unknown status
Start date
July 3, 2019
Completion date
April 30, 2026
Enrollment
267 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b, intermediate to high risk of hcc